Sandoz invests in major expansion of global headquarters in Holzkirchen, Germany

  • Expected investment will amount to approximately USD 50m
  • Decision to expand underlines confidence in growth potential of business
  • Modern campus facility will promote more collaborative ways of working

Holzkirchen, August 29, 2017 — Sandoz, the generic pharmaceuticals and biosimilars division of Novartis, announced today that it will further expand its global headquarters in Holzkirchen, near Munich. The expected investment will amount to approximately USD 50m.

Sandoz will begin construction of two …

/by

Lancet Haematology publishes data demonstrating Sandoz Rixathon® (biosimilar rituximab) matches efficacy and safety of reference biologic

  • Lancet Haematology publishes data from ASSIST-FL study of Sandoz Rixathon®, in patients with previously untreated advanced follicular lymphoma
  • ASSIST-FL, results of which were first announced in December 2017, achieved its primary endpoint1
  • Rixathon® received European Commission approval for use in all indications of the reference biologic in June 2017 2,3

Holzkirchen, August 29, 2017 – Lancet Haematology has published data from the ASSIST-FL trial demonstrating that the efficacy and safety of …

/by